Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
Garrison LP Jr, Pauly MV, Willke RJ, Neumann PJ. An overview of value, perspective, and decision context-A health economics approach: an ISPOR special task force report . Value Health. 2018;21(2):124–30.
Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, et al. The International decision support initiative reference case for economic evaluation: an aid to thought. Value Health. 2016;19(8):921–8.
Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-effectiveness in health and medicine. New York: Oxford University Press; 2017.
Johannesson M, Meltzer D, O'Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making. 1997;17(4):382–9.
Krol M, Papenburg J, Koopmanschap M, Brouwer W. Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics. 2011;29(7):601–19.
Krol M, Papenburg J, van Exel J. Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies. Pharmacoeconomics. 2015;33(2):123–35.
Weinstein MC, Russell LB, Gold MR, Siegel JE. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
Russell LB, Fryback DG, Sonnenberg FA. Is the societal perspective in cost-effectiveness analysis useful for decision makers? Jt Comm J Qual Improv. 1999;25(9):447–54.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.
Neumann PJ. Costing and perspective in published cost-effectiveness analysis. Med Care. 2009;47(7 Suppl 1):S28–32.
Adam T, Koopmanschap MA, Evans DB. Cost-effectiveness analysis: can we reduce variability in costing methods? Int J Technol Assess Health Care. 2003;19(2):407–20.
Stone PW, Chapman RH, Sandberg EA, Liljas B, Neumann PJ. Measuring costs in cost-utility analyses. Variations in the literature. Int J Technol Assess Health Care. 2000;16(1):111–24.
Mapping of HTA methodologies in EU and Norway [Internet]. European Commission. 2018. Available from: https://op.europa.eu/en/publication-detail/-/publication/4d364ea4-113a-11e8-9253-01aa75ed71a1/language-en/format-PDF/source-117287134#.
Basu A. Estimating costs and valuations of non-health benefits in cost-effectiveness analysis. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. New York: Oxford University Press; 2017.
Foreign Exchange Rates [Internet]. 2020. Available from: https://www.federalreserve.gov/releases/H10/Hist/default.htm.
Historical Consumer Price Index for All Urban Consumers (CPI-U) [Internet]. 2019. Available from: https://www.bls.gov/cpi/tables/supplemental-files/historical-cpi-u-201901.pdf.
Neumann PJ, Thorat T, Zhong Y, Anderson J, Farquhar M, Salem M, et al. A systematic review of cost-effectiveness studies reporting cost-per-DALY averted. PLoS ONE. 2016;11(12):e0168512.
Neumann PJ, Thorat T, Shi J, Saret CJ, Cohen JT. The changing face of the cost-utility literature, 1990–2012. Value Health. 2015;18(2):271–7.
CEA Registry Data Dictionary [Internet]. 2020. Available from: https://healtheconomicsdev.tuftsmedicalcenter.org/cear2/search/search.aspx.
Culyer A, Chalkidou K, Teerawattananon Y, Santatiwongchai B. Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays? F1000Res. 2018;7:72.
van Lier LI, Bosmans JE, van Hout HPJ, Mokkink LB, van den Hout WB, de Wit GA, et al. Consensus-based cross-European recommendations for the identification, measurement and valuation of costs in health economic evaluations: a European Delphi study. Eur J Health Econ. 2018;19(7):993–1008.
Pharmacoeconomic Guidelines Around The World [Internet]. 2020. Available from: https://tools.ispor.org/peguidelines/.
Methods for health economic evaluations : A guideline based on current practices in Europe [Internet]. 2015. Available from: https://www.eunethta.eu/wp-content/uploads/2018/03/Methods_for_health_economic_evaluations.pdf.
Health Intervention and Technology Assessment Program (HITAP). the Guide to Health Economic Analysis and Research (GEAR) 2020 [Available from: https://www.gear4health.com/.
van Dongen JM, El Alili M, Varga AN, Guevara Morel AE, Jornada Ben A, Khorrami M, et al. What do national pharmacoeconomic guidelines recommend regarding the statistical analysis of trial-based economic evaluations? Expert Rev Pharmacoecon Outcomes Res. 2019;1:1–11.
EunetHta Joint Action Work Package Subgroup, Heintz E, Gerber-Grote A, Ghabri S, Hamers FF, Rupel VP, et al. Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries. Pharmacoeconomics. 2016;34(1):59–76.
Moran D, Shrime MG, Nang S, Vycheth I, Vuthy D, Hong R, et al. Cost-effectiveness of craniotomy for epidural hematomas at a major government hospital in Cambodia. World J Surg. 2017;41(9):2215–23.
Padula WV, Phelps CE, Moran D, Earley C. Allocating provider resources to diagnose and treat restless legs syndrome: a cost-utility analysis. Sleep Med. 2017;38:44–9.
Hayajneh WA, Daniels VJ, James CK, Kanibir MN, Pilsbury M, Marks M, et al. Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach. BMC Infect Dis. 2018;18(1):119.
Raje N, Roodman GD, Willenbacher W, Shimizu K, Garcia-Sanz R, Terpos E, et al. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. J Med Econ. 2018;21(5):525–36.
Wolff E, Elfstrom KM, Haugen Cange H, Larsson S, Englund H, Sparen P, et al. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. Vaccine. 2018;36(34):5160–5.
Sher DJ, Tishler RB, Pham NL, Punglia RS. Cost-effectiveness analysis of intensity modulated radiation therapy versus proton therapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2018;101(4):875–82.
Cobiac LJ, Mizdrak A, Wilson N. Cost-effectiveness of raising alcohol excise taxes to reduce the injury burden of road traffic crashes. Inj Prev. 2019;25(5):421–7.
Kim SY, Nguyen C, Russell LB, Tomczyk S, Abdul-Hakeem F, Schrag SJ, et al. Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States. Vaccine. 2017;35(45):6238–47.
Mennini FS, Bini C, Marcellusi A, Rinaldi A, Franco E. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy. Hum Vaccin Immunother. 2018;14(8):1867–73.
Cobiac L, Vos T, Veerman L. Cost-effectiveness of weight watchers and the lighten up to a healthy lifestyle program. Aust N Z J Public Health. 2010;34(3):240–7.
Muangchana C, Riewpaiboon A, Jiamsiri S, Thamapornpilas P, Warinsatian P. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand. Vaccine. 2012;30(18):2839–47.
Sigei C, Odaga J, Mvundura M, Madrid Y, Clark AD, Kenya ProVac Technical Working G, et al. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda. Vaccine. 2015;33 Suppl 1:109–18.
Sarker AR, Sultana M, Mahumud RA, Van Der Meer R, Morton A. Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh. Hum Vaccin Immunother. 2018;14(1):189–98.
Zeng W, Halasa-Rappel YA, Baurin N, Coudeville L, Shepard DS. Cost-effectiveness of dengue vaccination in ten endemic countries. Vaccine. 2018;36(3):413–20.
Rajan PV, Qudsi RA, Dyer GSM, Losina E. The cost-effectiveness of surgical fixation of distal radial fractures: a computer model-based evaluation of three operative modalities. J Bone Joint Surg Am. 2018;100(3):e13.
Kantito S, Saokaew S, Yamwong S, Vathesatogkit P, Katekao W, Sritara P, et al. Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation. J Thromb Thrombolysis. 2018;45(2):281–90.
Kim DD, Basu A, Duffy SQ, Zarkin GA. Worked Example 1: the cost-effectiveness of treatment for individuals with alcohol use disorders: a reference case analysis. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in Health and Medicine, vol. 2. New York: Oxford University Press; 2017. p. 385–430.
Institute for Clinical and Economic Review. 2020–2023 Value Assessment Framework2020. Available from: https://icer-review.org/wp-content/uploads/2019/05/ICER_2020_2023_VAF_013120-4.pdf.
Kim DD, Neumann PJ. Analyzing the cost effectiveness of policy responses for COVID-19: the importance of capturing social consequences. Med Decis Making. 2020;40(3):251–3.
Meltzer D, Johannesson M. Inconsistencies in the "societal perspective" on costs of the panel on cost-effectiveness in health and medicine. Med Decis Making. 1999;19(4):371–7.
Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ. 1997;6(5):511–4.
Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16(1):33–64.
Nyman JA. Cost recommendations in the second edition of cost-effectiveness in health and medicine: a review. MDM Policy Pract. 2018;3(1): 62.
Nyman JA. Should the consumption of survivors be included as a cost in cost–utility analysis? Health Econ. 2004;13(5):417–27.
Russell LB. Completing costs: patients' time. Med Care. 2009;47(7 Suppl 1):S89–93.
Grosse SD, Pike J, Soelaeman R, Tilford JM. Quantifying family spillover effects in economic evaluations: measurement and valuation of informal care time. Pharmacoeconomics. 2019;37(4):461–73.
Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, et al. Future directions for cost-effectiveness analyses in health and medicine. Med Decis Making. 2018;38(7):767–77.
Brouwer WBF. The inclusion of spillover effects in economic evaluations: not an optional extra. Pharmacoeconomics. 2019;37(4):451–6.
Lin PJ, D'Cruz B, Leech AA, Neumann PJ, Sanon Aigbogun M, Oberdhan D, et al. Family and caregiver spillover effects in cost-utility analyses of Alzheimer's disease interventions. Pharmacoeconomics. 2019;37(4):597–608.
Lavelle TA, D'Cruz BN, Mohit B, Ungar WJ, Prosser LA, Tsiplova K, et al. Family spillover effects in pediatric cost-utility analyses. Appl Health Econ Health Policy. 2019;17(2):163–74.
Prosser LA, Wittenberg E. Advances in methods and novel applications for measuring family spillover effects of illness. Pharmacoeconomics. 2019;37(4):447–50.
Panzer AD, Emerson JG, D'Cruz B, Patel A, Dabak S, Isaranuwatchai W, et al. Growth and capacity for cost-effectiveness analysis in Africa. Health Econ. 2020.